ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

RZLT Rezolute Inc

3,31
0,34 (11,45%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Rezolute Inc RZLT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,34 11,45% 3,31 00:53:39
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,06 2,98 3,38 3,31 2,97
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
23.4.202414:00GLOBEPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024..
11.3.202422:03EDGAR2Form 8-K - Current report
11.3.202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202413:30GLOBERezolute Reports Validation of the Potential Use of RZ358..
27.2.202414:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202423:00EDGAR2Form 8-K - Current report
21.2.202417:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202423:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202422:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.2.202422:10EDGAR2Form 8-K - Current report
13.2.202422:05GLOBERezolute Reports Second Quarter Fiscal 2024 Results and..
29.1.202423:15EDGAR2Form 8-K - Current report
25.1.202418:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.1.202418:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.1.202418:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.1.202418:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202414:00GLOBERezolute Expands Leadership Team with Appointment of Daron..
23.1.202414:00GLOBERezolute Receives Innovation Passport Designation from the..
14.12.202322:01EDGAR2Form 8-K - Current report
14.12.202314:00GLOBERezolute Initiates Phase 3 Clinical Study for RZ358 in..
13.12.202314:00GLOBERezolute Completes Enrollment of its Phase 2 Study in..
30.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
22.11.202323:16EDGAR2Form S-3/A - Registration statement under Securities Act of..
22.11.202322:35EDGAR2Form 8-K - Current report
17.11.202314:00GLOBERezolute to Participate in BTIG’s 3rd Annual Ophthalmology..
15.11.202315:08EDGAR2Form S-3 - Registration statement under Securities Act of..
13.11.202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202322:13EDGAR2Form 8-K - Current report
13.11.202322:05GLOBERezolute Reports First Quarter Fiscal 2024 Results
18.10.202322:30EDGAR2Form 8-K - Current report
17.10.202314:00GLOBERezolute Receives Priority Medicines (PRIME) Eligibility..
13.10.202322:47EDGAR2Form 8-K - Current report
13.10.202322:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11.10.202314:00GLOBERezolute Announces Further Evidence of RZ358’s Efficacy in..
14.9.202322:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
14.9.202322:10EDGAR2Form 8-K - Current report
14.9.202322:05GLOBERezolute Reports Full Year Fiscal 2023 Results and..
06.9.202313:00GLOBERezolute to Participate in Upcoming Investor Conferences in..
06.7.202317:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.6.202322:05GLOBERezolute to Initiate a Pivotal Phase 3 Study of RZ358 in..
11.5.202322:05GLOBERezolute Reports Third Quarter Fiscal 2023 Results and..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock